iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

1146 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-21

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with acute ST-elevation myocardial infarction (STEMI), 40-60% have multi-vessel disease with an increased cardiovascular morbidity and mortality. Although it is not recommended to revascularize noninfarct lesions during the acute intervention, recent investigations suggest the opposite and show improved outcome after direct revascularization of noninfarct lesions. It is undesirable to risk procedure-related complications by treating noninfarct lesions without impaired flow. It is currently unknown whether pressure guided revascularization of noninfarct lesions in the acute phase improves outcome compared to the current guidelines.

The iMODERN trial aims to compare an iFR-guided intervention of noninfarct lesions during the acute intervention with a deferred stress perfusion CMR-guided strategy during the outpatient follow-up, to determine the optimal therapeutic approach for STEMI patients with multivessel lesions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CMR or Angiography for FFR-guided Revascularisation

NCT03408912

STEMI

UNKNOWN NA

Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease

NCT06246188

Coronary Artery Disease

NOT_YET_RECRUITING

Non-invasive and Invasive Assessment of Coronary Artery Disease

NCT01823809

Coronary Artery Disease

TERMINATED NA

Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion:a Randomized H215O PET/CT Study

NCT01876589

Coronary Artery Disease

UNKNOWN NA

Cardiac MR (CMR) in Cardiac Resynchronization Therapy Non-responders

NCT01367691

Heart Failure

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design:

The study is a prospective, randomized controlled, multicentre study.

Study population:

The research population will be recruited from the general patient population presenting with an acute STEMI. Patients treated with successful primary PCI and one or more additional significant coronary lesions in another coronary artery will be enrolled in the study. A total of 1,146 consecutive patients will be included.

Intervention:

The patients will be randomized 1:1, to (A) an active treatment arm with complete, iFR-guided revascularization of every noninfarct coronary lesion \>50% and iFR ≤0.89; (B) a deferred treatment arm, in which patients will undergo an adenosine stress perfusion CMR scan within 6 weeks after STEMI, with revascularization of the noninfarct coronary lesions with associated perfusion defects.

Main study parameters/endpoints:

The primary end point consists of a combined outcome, including all-cause death, recurrent MI and hospitalization for heart failure at 3 years follow-up.

Duration:

Anticipated recruitment is 2 years. Follow-up will be performed at 6 months, 12 months, 3 years and 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction Multi Vessel Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1:1 randomization to (A) an active treatment arm with complete, iFR-guided revascularization of every noninfarct coronary lesion \>50% and iFR ≤0.89; or (B) a deferred treatment arm, in which patients will undergo an adenosine stress perfusion CMR scan within 6 weeks after STEMI, with revascularization of the noninfarct coronary lesions with associated perfusion defects.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active iFR-guided revascularization

Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment

Group Type EXPERIMENTAL

iFR

Intervention Type DIAGNOSTIC_TEST

Treatment guided by instantaneous wave-free ratio

Deferred CMR-guided revascularization

Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging

Group Type ACTIVE_COMPARATOR

CMR

Intervention Type DIAGNOSTIC_TEST

Treatment guided by stress perfusion CMR

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iFR

Treatment guided by instantaneous wave-free ratio

Intervention Type DIAGNOSTIC_TEST

CMR

Treatment guided by stress perfusion CMR

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical presentation of STEMI and successful primary PCI within 12 hours from onset of symptoms.
* One or more other, noninfarct coronary artery lesions of \>50% stenosis and feasible to be revascularized (i.e. minimal diameter 2mm).

Exclusion Criteria

* History of myocardial infarction.
* Hemodynamic instability, respiratory failure, Kilips class ≥III.
* Known GFR\<30 ml/min.
* Known contra-indications for stress CMR (e.g.: severe claustrophobia, metal implants, severe renal failure, severe astma).
* Refusal or inability to provide informed consent.
* Life expectancy due to noncardiovascular co-morbidity of less than 12 months.
* Chronic total occlusion.
* Left main stem stenosis (\>50%).
* Residual noninfarct lesion in infarct coronary artery.
* Complex (e.g. bifurcation) noninfarct target lesions.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No